129 results match your criteria sickness-like reactions


Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Cutaneous Adverse Reactions: A Review.

Dermatitis 2021 May-Jun 01;32(3):133-139

We are entering a new stage of the severe acute respiratory syndrome coronavirus 2 pandemic with the initiation of large-scale vaccination programs globally. In these circumstances, even rare adverse effects of vaccines may be encountered more often, if millions of people are to be vaccinated in a short period. Vaccination has the potential for causing cutaneous adverse effects. Read More

View Article and Full-Text PDF

Adverse Reactions Induced by Minocycline: A Review of Literature.

Curr Drug Saf 2021 Jan 19. Epub 2021 Jan 19.

Government Medical College, Kottayam. India.

Background: Minocycline is a tetracycline antibiotic that is widely used to treat infections, and is a first-line oral antibiotic in the treatment of moderate to severe inflammatory acne. Although it has high efficacy, several adverse reactions, including life-threatening ones have been reported in association with its use.

Objective: To identify all the potential adverse reactions due to minocycline and analyze them in terms of the number of cases reported so far, salient features, severity and clinical outcome. Read More

View Article and Full-Text PDF
January 2021

Cutaneous drug eruptions including serum sickness-like reaction, symmetrical drug-related intertriginous and flexural exanthema, and drug-induced lupus.

Clin Dermatol 2020 Nov - Dec;38(6):641-647. Epub 2020 Jun 30.

Wake Forest University School of Medicine, Department of Dermatology, Winston-Salem, North Carolina, USA. Electronic address:

Cutaneous manifestations of drug reactions are common yet vary widely in their appearance and degree of internal organ involvement. Serum sickness--like reactions, symmetrical drug-related intertriginous and flexural exanthem, granulomatous drug eruption, pseudolymphoma, and drug-induced lupus are medication-induced conditions with dermatologic presentations. Many of the conditions discussed are relatively rare but nonetheless demand our attention and understanding. Read More

View Article and Full-Text PDF
January 2021

Pediatric drug eruptions.

Clin Dermatol 2020 Nov - Dec;38(6):629-640. Epub 2020 Jun 29.

Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address:

Drug eruptions in children are common but in general less studied than their adult counterparts. Aside from having significant impact on the child's health and quality of life, these reactions can limit what medications the patient can receive in the future. Familiarity with pediatric drug eruptions is important for accurate diagnosis and to prevent future recurrence or ineffective therapy. Read More

View Article and Full-Text PDF
January 2021

Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders.

Curr Drug Metab 2021 ;22(2):99-107

Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Cutaneous manifestations due to drugs used in the treatment of gastrointestinal disorders are multiple and common. Adequate diagnosis is of great importance, bearing in mind that the therapeutic regimen depends on its diagnosis. In this review, we provided an overview of the most common drug-induced skin lesions with a detailed explanation of the disease course, presentation and treatment, having in mind that in recent years, novel therapeutic modalities have been introduced in the treatment of various gastrointestinal disorders, and that incidence of cutaneous adverse reactions has been on the rise. Read More

View Article and Full-Text PDF
January 2021

Differentiating Between β-Lactam-Induced Serum Sickness-Like Reactions and Viral Exanthem in Children Using a Graded Oral Challenge.

J Allergy Clin Immunol Pract 2021 02 6;9(2):916-921. Epub 2020 Sep 6.

Department of Pediatrics, Division of Allergy and Clinical Immunology, Montreal Children's Hospital, Montreal, Quebec, Canada.

Background: Serum sickness-like reactions (SSLRs) are defined by the presence of rash (primarily urticaria) and joint complaints (arthralgia/arthritis) that are believed to occur due to a non-IgE-mediated response to medications. However, similar reactions can occur due to viral infections, and it can be difficult to distinguish between the two. This may lead to unnecessary avoidance of the culprit antibiotic. Read More

View Article and Full-Text PDF
February 2021

Serum sickness-like reactions in Iranian children: a registry-based study in a referral center.

Allergol Immunopathol (Madr) 2020 Sep - Oct;48(5):424-429. Epub 2020 Jul 8.

Department of Allergy and Clinical Immunology, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:

Introduction And Objectives: Considering that no studies have been done on a comprehensive review of Serum sickness-like reactions patients (SSLRs) at a referral center in Iran so far, this study aimed to determine the clinical and laboratory characteristics of children with SSRL in Tehran Children's Medical Center.

Patients: The present study was a registry-based study in which the data of 94 SSLRs patients registered in a two-year period were investigated. Confirmation of fever, rash, urticaria, arthralgia / arthritis and history of antibiotic consumption up to three weeks before were the criteria for the diagnosis. Read More

View Article and Full-Text PDF

Beta-lactam allergy in the paediatric population.

Paediatr Child Health 2020 Feb 6;25(1):62-63. Epub 2020 Feb 6.

Canadian Paediatric Society, Allergy Section, Ottawa, Ontario.

Beta-lactam allergy is commonly diagnosed in paediatric patients, but over 90% of individuals reporting this allergy are able to tolerate the medications prescribed after evaluation by an allergist. Beta-lactam allergy labels are associated with negative clinical and administrative outcomes, including use of less desirable alternative antibiotics, longer hospitalizations, increasing antibiotic-resistant infections, and greater medical costs. Also, children with true IgE-mediated allergy to penicillin medications are often advised to avoid all beta-lactam antibiotics, including cephalosporins, which is likely unnecessary in greater than 97% of those reporting penicillin allergies. Read More

View Article and Full-Text PDF
February 2020

A Case of Serum Sickness-Like Reaction in an Adult Treated with Omalizumab.

Mil Med 2020 06;185(5-6):e912-e913

Allergy/Immunology, Wilford Hall Ambulatory Surgical Center, 1100 Wilford Hall Loop, Lackland AFB, TX 78236.

Omalizumab has been safely used to treat asthma and urticaria. We report a case of serum sickness-like reaction in a patient treated with omalizumab for chronic idiopathic urticaria/angioedema. An adult female experienced episodic urticaria/angioedema without repeatable trigger, ultimately receiving diagnosis of chronic idiopathic urticaria/angioedema. Read More

View Article and Full-Text PDF

A rapid desensitization protocol in a case of drotaverine-induced serum sickness-like reaction in a pregnant woman: A case report.

Exp Ther Med 2019 Dec 7;18(6):5105-5107. Epub 2019 Nov 7.

Department of Allergy, 'Dr. Carol Davila' Nephrology Clinical Hospital, 010731 Bucharest, Romania.

Drotaverine is an antispasmodic drug used to treat gastrointestinal and genitourinary smooth muscle spasms. There are very few hypersensitivity reactions reported. Serum sickness-like disease is an immune-complex-mediated hypersensitivity reaction that presents with some typical features that include rash, fever and articular impairment sometimes associated with liver and renal dysfunctions, beginning 1-2 weeks after exposure to a culprit drug. Read More

View Article and Full-Text PDF
December 2019

Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions.

Curr Pharm Des 2019 ;25(36):3840-3854

Department of Pediatric Allergy and Immunology, University of Health Sciences, Ankara Child Health and Diseases Hematology Oncology Training and Research Hospital, Ankara, Turkey.

Drug hypersensitivity reactions are clinically heterogenous ranging from mild to severe. Most drug hypersensitivity reactions are accompanied by cutaneous manifestations. Fever, mucous membrane involvement, large blisters, facial oedema, pustulosis and visceral involvement are clinical features that lead to suspicion of severe adverse drug reactions. Read More

View Article and Full-Text PDF

An Update on the Management of Severe Cutaneous Drug Hypersensitivity Reactions.

Curr Pharm Des 2019 ;25(36):3881-3901

Department of Pediatric Allergy and Immunology, Mersin University, Faculty of Medicine, Mersin, Turkey.

Severe cutaneous drug hypersensitivity reactions involve of different mechanisms , some of which are life-threatening, such as Stevens-Johnson syndrome/toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis, generalized bullous fixed drug eruptions, serum sickness and serum sickness-like reaction and drug-induced vasculitis. These reactions may have substantial morbidity and mortality. In the past years, successive studies have provided new evidence regarding the pathogenesis of some of these severe reactions and revealed that underlying mechanisms are highly variable. Read More

View Article and Full-Text PDF

Antibiotic Hypersensitivity Mechanisms.

Pharmacy (Basel) 2019 Aug 27;7(3). Epub 2019 Aug 27.

Department of Pharmaceutical Sciences, School of Pharmacy, Rueckert-Hartman College of Health Professions, Regis University, Denver, CO 80221, USA.

Antibiotics are commonly prescribed to treat a variety of bacterial infections. As with all medications, hypersensitivity reactions may occur and clinicians should be able to recognize them accurately and recommend appropriate management. Antibiotic related hypersensitivity reactions may be one of four different types: Type I reactions, which are IgE mediated and may lead to anaphylaxis; Type II reactions that are antibody-mediated and may result in thrombocytopenia, neutropenia, or hemolytic anemia; Type III reaction that involves an immune complex formation such as vasculitis; and Type IV reactions that consist of four subtypes and typically include a rash of varying level of severity with or without systemic signs and symptoms. Read More

View Article and Full-Text PDF

A review of cutaneous hypersensitivity reactions in infants: From common to concerning.

Pediatr Dermatol 2019 May 25;36(3):274-282. Epub 2019 Apr 25.

Section of Dermatology, Department of Medicine and Pediatrics, University of Chicago, Chicago, Illinois.

Cutaneous hypersensitivity reactions in infants present in a variety of patterns. These skin eruptions can be dramatic, causing alarm in parents and medical personnel. Many of these syndromes have overlapping features, which adds to the confusion and uncertainty regarding diagnosis and management. Read More

View Article and Full-Text PDF

Dermatomyositis associated with omalizumab therapy for severe asthma: a case report.

Allergy Asthma Clin Immunol 2019 17;15. Epub 2019 Jan 17.

3Department of Medicine, Western University, London, ON Canada.

Background: Omalizumab is a humanized monoclonal antibody widely used for treatment of persistent allergic asthma and antihistamine-refractory chronic urticaria. Immediate adverse events to omalizumab are well characterized. Delayed anaphylactoid and serum sickness-like reactions have also been described; however, their relationship to the drug remains uncertain, and the frequency is unknown. Read More

View Article and Full-Text PDF
January 2019

Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.

Mult Scler Relat Disord 2018 Nov 11;26:52-54. Epub 2018 Sep 11.

Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Italy; Ospedale Policlinico San Martino IRCCS, Genoa, Italy; Center of Excellence for Biomedical Research (CEBR), University of Genoa, Genoa, Italy.

Background: Alemtuzumab is a monoclonal antibody approved for relapsing-remitting multiple sclerosis (RRMS). The only report of Serum Sickness (SS) in a MS patient occurred during treatment with natalizumab. Non-protein drugs, such as some antibiotics, may induce "SS-like" reactions (SSLR), whose clinical and laboratory features may partially overlap with the traditional SS. Read More

View Article and Full-Text PDF
November 2018

Demographic and clinical characteristics of patients with serum sickness-like reaction.

Clin Rheumatol 2018 May 9;37(5):1389-1394. Epub 2017 Aug 9.

Department of Pediatric rheumatology, Selçuk University Medical School, Konya, Turkey.

In this study, we aimed to review the demographic, clinical, and laboratory characteristics of patients who were followed up and treated with the diagnosis of serum sickness-like reactions (SSLR) in our pediatric rheumatology clinic retrospectively and emphasize the importance of early diagnosis and treatment. The files of 29 patients who were hospitalized in the pediatric rheumatology clinic between September 2016 and March 2017 with the diagnosis of type 3 hypersensitivity reaction were reviewed retrospectively. Patient records including C-reactive protein, erythrocyte sedimentation rate, serum electrolytes, blood glucose, urea, and liver function were recorded by using the computerized patient database. Read More

View Article and Full-Text PDF

Serum sickness-like reaction after the treatment of cellulitis with amoxicillin/clavulanate.

BMJ Case Rep 2016 Oct 18;2016. Epub 2016 Oct 18.

Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Serum sickness-like reaction is a rare disease presentation. We describe a case of a man aged 58 years who presented with acute-onset polyarthralgia, intense pruritus of hands and feet, fever to 39.5°C and leucocytosis to 17. Read More

View Article and Full-Text PDF
October 2016

Hypersensitivity and immunologic reactions to biologics: opportunities for the allergist.

Authors:
David A Khan

Ann Allergy Asthma Immunol 2016 08;117(2):115-20

Department of Internal Medicine, Division of Allergy and Immunology, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address:

Objective: There has been a great expanse in the use of biological agents during the past decade. However, there are significant differences between biologics and typical pharmaceutical drugs. This review focuses on 3 separate types of adverse reactions to biologics, namely high cytokine reactions, hypersensitivity reactions, and secondary immunodeficiency. Read More

View Article and Full-Text PDF

Piperacillin-Tazobactam Induced Interstitial Nephritis, Hepatitis and Serum Sckness-Like Illness.

J Ark Med Soc 2016 Jun;112(14):278-80

Objective: To describe a patient who developed acute interstitial nephritis, hepatitis and serum sickness-like syndrome after receiving piperacillin-tazobactam (zosyn) therapy.

Case Summary: A 30-year-old woman received a 7-day course of piperacillin-tazobactam as empiric treatment for pneumonia. The patient's kidney function worsened and she turned anuric needing dialysis. Read More

View Article and Full-Text PDF

Understanding the mechanisms in accelerated drug reactions.

Curr Opin Allergy Clin Immunol 2016 08;16(4):308-14

aAllergy Unit bResearch Laboratory, IBIMA-Regional University Hospital of Malaga-UMA, Malaga, Spain.

Purpose Of Review: The purpose is to understand the underlying mechanisms of accelerated allergic reactions to drugs, defined here as reactions occurring between 1 and 24 h after drug intake.

Recent Findings: Recent publications have shown that accelerated reactions are T cell-mediated, although an IgE mechanism cannot be ruled out in some cases.

Summary: Classification of allergic reactions to drugs is complex. Read More

View Article and Full-Text PDF

Safety profile of etifoxine: A French pharmacovigilance survey.

Fundam Clin Pharmacol 2016 Apr 26;30(2):147-52. Epub 2016 Jan 26.

Regional Pharmacovigilance Center of Lyon, University Hospitals, 162, avenue Lacassagne, 69003, Lyon, France.

Etifoxine chlorhydrate is a benzoxazine derivative approved for the treatment of psychosomatic manifestations of anxiety since 1979. Previously labeled adverse drug reactions (ADRs) only include drowsiness, benign cutaneous reactions, and acute hypersensitivity reactions. The objectives were to examine recent data on etifoxine-related ADR by reviewing Individual Case Safety Reports (ICSRs) recorded in France especially unexpected ADRs. Read More

View Article and Full-Text PDF

Drug hypersensitivity in children: report from the pediatric task force of the EAACI Drug Allergy Interest Group.

Allergy 2016 Feb 17;71(2):149-61. Epub 2015 Nov 17.

Department of ENT and Pediatrics, AMC, Amsterdam, The Netherlands.

When questioned, about 10% of the parents report suspected hypersensitivity to at least one drug in their children. However, only a few of these reactions can be confirmed as allergic after a diagnostic workup. There is still a lack of knowledge on drug hypersensitivity (DH) epidemiology, clinical spectrum, and appropriate diagnostic methods particularly in children. Read More

View Article and Full-Text PDF
February 2016

Epidemiology of severe drug hypersensitivity.

Semin Cutan Med Surg 2014 Mar;33(1):2-9

Division of Dermatology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Canada. E-mail:

Epidemiological studies of severe drug hypersensitivities are important to understanding the morbidity and mortality of this heterogeneous group of disorders. These insights also allow greater identification of at-risk patient groups. However, epidemiological studies of drug hypersensitivity reactions are challenging due to the variable diagnostic criteria applied and incomplete data sets studied. Read More

View Article and Full-Text PDF

Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.

Antimicrob Agents Chemother 2014 Jun 17;58(6):3137-43. Epub 2014 Mar 17.

Harvard Medical School, Boston Massachusetts, USA Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.

The objective of the present study was to assess the safety and tolerability of cefazolin therapy among patients with methicillin-sensitive Gram-positive bacterial infections who develop non-IgE-mediated hypersensitivity reactions (HSRs) to nafcillin. In this retrospective cohort analysis of the Outpatient Parenteral Antimicrobial Therapy program at the Massachusetts General Hospital from 2007 through 2013, we identified patients switched from nafcillin to cefazolin after an immune-mediated HSR. We reviewed patient demographics, details about the original HSR, and outcomes after the switch to cefazolin therapy. Read More

View Article and Full-Text PDF

A case of serum sickness-like reaction and anaphylaxis - induced simultaneously by rifampin.

Allergy Asthma Immunol Res 2014 Mar 27;6(2):183-5. Epub 2013 Sep 27.

Department of Allergy, Asthma, and Clinical Immunology, Chonnam National University Medical School, Gwangju, Korea.

Rifampin is commonly used as a first-line anti-tuberculosis drug, but it can induce a serum sickness-like reaction or anaphylaxis. However, it is possible for 1 drug antigen to induce 2 or more simultaneous immunologic reactions. Here, we report a case of a serum-sickness-like reaction and anaphylaxis induced concurrently by rifampin. Read More

View Article and Full-Text PDF

Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris.

J Pharmacol Pharmacother 2013 Jan;4(1):33-8

Department of Pharmacology, Veer Chandra Singh Garhwali Government Medical Sciences and Research Institute, Srikot, Uttarakhand, India.

Introduction: To compare the efficacy and tolerability of Ivabradine (IVA) and Ranolazine (RAN) in chronic angina patients.

Materials And Methods: This was a follow-on, open-label trial conducted in a tertiary care hospital of Uttarakhand. Thirty patients each taking IVA 5 mg twice daily or RAN 500 mg twice daily were distributed to the respective groups. Read More

View Article and Full-Text PDF
January 2013

Intestinal mucosal permeability of children with cefaclor-associated serum sickness-like reactions.

Eur J Pediatr 2013 Apr 8;172(4):537-43. Epub 2013 Jan 8.

Department of Laboratory Medicine, Wuhan Medical and Health Center for Women and Children, Tongji Medical College, Huazhong University of Science and Technology, 100 Xianggang Rd., Jiang An District, Wuhan, Hubei 430016, People's Republic of China.

Although the serum sickness-like reaction (SSLR) in children after the administration of cefaclor has long been recognized, the exact mechanism of cefaclor-associated SSLR remains unclear. This study aims to investigate the association between intestinal mucosal permeability and cefaclor-associated SSLR in children. A total of 82 pediatric patients with upper respiratory tract infection following the cefaclor therapy was divided into cefaclor-associated SSLR positive group and negative group based on the presence or absence of SSLR after taking cefaclor, and 30 healthy volunteers served as control group. Read More

View Article and Full-Text PDF

Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry.

Ann Rheum Dis 2013 Jun 21;72(6):1026-31. Epub 2012 Dec 21.

Service de Rhumatologie, Centre National de Références des Maladies Auto-Immunes Systémiques Rares, Hôpitaux Universitaires de Strasbourg, Immunorhumathologie Moléculaire, INSERM UMR S 1109, Université de Strasbourg, Strasbourg, France.

Objectives: To evaluate the efficacy and safety of rituximab in patients with primary Sjögren's syndrome (pSS).

Methods: The AutoImmune and Rituximab registry has included 86 patients with pSS treated with rituximab, prospectivey followed up every 6 months for 5 years.

Results: Seventy-eight patients with pSS (11 men, 67 women), who already had at least one follow-up visit, were analysed. Read More

View Article and Full-Text PDF

Prolonged fever after Infliximab infusion.

World J Gastrointest Pharmacol Ther 2012 Jun;3(3):34-5

Jennifer Katz, Michael Frank, New York University Medical Center, New York, NY 10016, United States.

Pharmacologic management for ulcerative colitis (UC) has recently been expanded to include anti- tumor necrosis factor (TNF) therapy for severe disease. Infliximab, a chimeric monoclonal antibody directed again TNF α was first tested in patients with Crohn's disease. In addition to serious infections, malignancy, drug induced lupus and other autoimmune diseases, serum sickness-like reactions, neurological disease, and infusion reactions further complicate the use of Infliximab. Read More

View Article and Full-Text PDF